Evidence map›Paper›PMID 31866629›Full record

ArticleInternal medicine (Tokyo, Japan)2020

Long-term Successful Treatment of Rituximab for Steroid-resistant Minimal Change Nephrotic Syndrome and Idiopathic Thrombocytopenic Purpura.

Mana Nishikawa, Noriaki Shimada, Tomohiro Kawazoe, Ryo Sawaki, Haruka Ikuta, Motoko Kanzaki, Kosuke Fukuoka, Masaki Fukushima, Kenichiro Asano

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 76% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Mana NishikawaDepartment of Nephrology, Kurashiki Central Hospital, Japan.
Noriaki ShimadaDepartment of Nephrology, Kurashiki Central Hospital, Japan.
Tomohiro KawazoeDepartment of Nephrology, Kurashiki Central Hospital, Japan.
Ryo SawakiDepartment of Nephrology, Kurashiki Central Hospital, Japan.
Haruka IkutaDepartment of Nephrology, Kurashiki Central Hospital, Japan.
Motoko KanzakiDepartment of Nephrology, Kurashiki Central Hospital, Japan.
Kosuke FukuokaDepartment of Nephrology, Kurashiki Central Hospital, Japan.
Masaki FukushimaDepartment of Internal Medicine, Shigei Research Institute Hospital, Japan.
Kenichiro AsanoDepartment of Nephrology, Kurashiki Central Hospital, Japan.
Kurashiki Central Hospital · JPShigei Medical Research Institute · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 22-year-old woman had been diagnosed with idiopathic thrombocytopenic purpura (ITP) 5 years earlier. After undergoing splenectomy, she relapsed frequently following prednisolone tapering. She was complicated with minimal change nephrotic syndrome (MCNS) while taking 20 mg of prednisolone. Despite treatment with prednisolone, cyclosporin and low-density lipoprotein-apheresis, MCNS and ITP did not improve. We added rituximab in 4 weekly infusions of 375 mg/m

Indexed as

AdultAntineoplastic Agents, ImmunologicalFemaleHumansNephrotic SyndromePurpura, Thrombocytopenic, IdiopathicRituximabTreatment OutcomeYoung AdultAntineoplastic Agents, ImmunologicalRituximabidiopathic thrombocytopenic purpuraminimal change nephrotic syndromeregulatory T cellrituximab

Identifiers

PMID31866629
PMCPMC7184077
OpenAlexW2994711079

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.